EARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
Double antiplatelet therapy, which includes aspirin and platelet P2Y12 receptor inhibitors (hereinafter P2Y12 inhibitor) is the main component of treatment and secondary prevention after ACS. In recent years, the issue of determining whether it is expedient for P2Y12 inhibitors to be early prescribe...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«REMEDIUM GROUP» Ltd.
2018-12-01
|
| Series: | Атеротромбоз |
| Subjects: | |
| Online Access: | https://www.aterotromboz.ru/jour/article/view/168 |